Analysis of the Association between Neuraminidase Inhibitors and Neuropsychiatric Adverse Events Using Japanese Adverse Drug Event Report (JADER)
10.11256/jjdi.18.38
- VernacularTitle:医薬品副作用データベース（JADER）を用いたノイラミニダーゼ 阻害剤と精神神経症状の関連性の検討
- Author:
Natsumi Ueda
;
Yamato Kato
;
Junko Abe
;
Yoko Nakayama
;
Toshinobu Matsui
;
Yuuki Hane
;
Sayaka Sasaoka
;
Yumi Motooka
;
Haruna Hatahira
;
Yasutomi Kinosada
;
Zenichiro Kato
;
Mitsuhiro Nakamura
- Publication Type:Journal Article
- Keywords:
neuraminidase inhibitors;
neuropsychiatric adverse events;
Japanese Adverse Drug Event Report;
oseltamivir
- From:Japanese Journal of Drug Informatics
2016;18(1):38-45
- CountryJapan
- Language:English
-
Abstract:
There have been concerns that neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) cause neuropsychiatric adverse events (NPAEs). We evaluated the number of relevant reports, reporting ratio, and reporting odds ratio (ROR) by using spontaneous reporting database, such as the Japanese Adverse Drug Event Report (JADER) (April 2004 to July 2014). The RORs of oseltamivir, zanamivir, laninamivir, and peramivir were 11.8 (95% confidence interval (CI), 10.8-13.0), 47.0 (95% CI, 40.0-55.3), 9.5 (95% CI, 6.8-13.2), and 3.3 (95% CI, 2.1-5.1), respectively. The lower limit of the ROR 95% CI of NPAEs of all neuraminidase inhibitors was ≥1. We analyzed the association of age and gender with NPAEs in patients treated with oseltamivir using a logistic regression model. The adjusted ROR of NPAEs was 66.9 (95% CI, 50.3-88.9) in male patients treated with osletamivir aged 10-19 years. The adjusted RORs of NPAEs were increased in male and female patients under the age of 20 years. Neuraminidase inhibitors including oseltamivir treatment could be associated with NPAEs. Therefore, these drugs should be used carefully in clinical practice.
